Daiichi Sankyo Company, Limited

Sankyo Company, Limited

Polymatech Co., Ltd.

Nec Corporation

Asahi Kasel Emd Corp.

Kabushiki Kaisha Kyosan Seisakusho

Masami Arai

Hideki Kobayashi

Toshio Kaneko

Naoki Terasaka

Hiroyuki Kobayashi

Takeshi Masuda

Takeshi Honda

Hideaki Watanabe

Hideki Kubota

Tomowo Kobayashi

Toshinori Takatsuka

Nobuyuki Ohkawa

Tetsuo Hiraoka

Yoshifumi Honmatsu

Daisuke Takano

Masayuki Ishizaki

Tedi Kunthady

Toshifumi Tsuda

Yoshiyuki Kobayashi

Teiji Wada

Masao Shiozaki

Makoto Yamashita

Noboru Ishida

Toshio Onoda

Yuzuru Akamatsu

Masahiro Nishijima

Hiroki Iwasaki

Itsuo Yuzurihara

Kyoko Hara

Toshiki Tabuchi

Desired is development of novel CDN derivatives having STING agonist activity; and a therapeutic agents and/or therapeutic methods using the novel CDN derivatives for diseases associated with STING agonist activity. Further desired is development of a therapeutic agents and/or therapeutic methods capable of delivering the novel CDN derivatives specifically to targeted cells and organs for diseases associated with STING agonist activity. The present invention provides novel CDN derivatives having potent STING agonist activity, and antibody-CDN derivative conjugates including the novel CDN derivatives.

Cyclic dinucleotide derivative based antibody-drug conjugates

A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, hyper-LDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group, and Ris a hydrogen atom or a hydroxy group. 

5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative

A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group. 

Piperidinylpyrazolopyridine derivative

Provided are a decorative sheet which is enhanced in durability of an edge portion of a soft feel layer thereof and which is unlikely to suffer breakage, a method of manufacturing such a decorative sheet, a decorative molded body, and a decorative key sheet. A compressed portion formed by crushing a foam layer in a thickness direction is provided at a side surface of an edge portion of a decorative sheet with a soft touch feeling.

Decorative sheet, decorative molded body, decorative key sheet, and decorative sheet manufacturing method

Provided are a pointing device allowing accurate depressing operation on a key top and involving no erroneous input or erroneous operation, and a key sheet for the pointing device. On the back surface of a base sheet () of a key sheet () for a pointing device, an accommodating portion () for a magnet (), for accommodating portion greatly protrudes toward a board (P) beyond a pusher () is provided. When the key top () is depressed, the accommodating portion () and the magnet () come into contact with the board (P), and causes the depressed key top () to tilt using the point of contact as a fulcrum, thereby pressing the pusher () against a contact switch (Pi, Po). Thus, it is possible to reduce the thickness and weight of the pointing device () and the key sheet () for the pointing device. Further, a reduction is achieved in terms of the possibility of erroneous input and erroneous operation, making it possible to reliably effect confirmation input.

Pointing device and key sheet for pointing device

Neuraminic acid derivatives, their preparation and their medical use

Compounds of formula (I): ##STR1## in which: R.sup.1 is hydroxy, protected hydroxy, fluorine, or --OP(O)(OH).sub.2 ; R.sup.2 and R.sup.3 are independently optionally substituted C.sub.6 -C.sub.20 aliphatic acyl; R.sup.4 is hydroxy, protected hydroxy, or --OP(O)(OH).sub.2, where at least one of R.sup.1 and R.sup.4 is --OP(O)(OH).sub.2 ; and R.sup.5 is hydroxy, protected hydroxy, or fluorine; provided that, except where at least one of R.sup.1 and R.sup.5 is fluorine, then at least one of R.sup.2 and R.sup.3 is a substituted C.sub.6 -C.sub.20 aliphatic acyl having (i) at least one halogen substituent and (ii) at least one substituent selected from the group consisting of halogen, hydroxy and C.sub.6 -C.sub.20 aliphatic acyloxy or at least one of R.sup.2 and R.sup.3 is a substituted C.sub.6 -C.sub.20 aliphatic acyl which is substituted by at least one halogen-substituted C.sub.6 -C.sub.20 aliphatic carboxylic acyloxy; have Lipid A-like activity and may be used for the treatment, prophylaxis, diagnosis and support of an animal suffering a disease or disorder arising from a deficiency in the immune system or from a tumor. They may be prepared by phosphorylation of corresponding compounds lacking a phosphoryl group.

Lipid A analogs having immunoactivating and anti-tumor activity

In a wireless communication apparatus arranged by an indoor unit, an outdoor unit, and a cable used to connect the indoor unit with the outdoor unit, a gain of an amplifier is automatically set. This amplifier amplifies a lowered level of a signal caused by a cable loss. To perform such an automatic gain setting operation, a cable loss equalization system is used in this wireless communication apparatus. The cable loss equalization system compensates for a reduction in a level of a main signal caused by the cable. The indoor unit comprises: an amplifier for amplifying at least one of a main transmit signal and a main receive signal; a first power source for supplying a first power source voltage to the indoor unit and a second power source of the outdoor unit; transmitting means for transmitting the first power source voltage via the cable to the outdoor unit; receiving means for receiving a second power source voltage supplied to the second power source of the outdoor unit from this outdoor unit; and a first control unit for measuring a voltage difference between the first power source voltage and the second power source voltage to thereby perform a gain setting operation of the amplifier.

Cable loss equalization system used in wireless communication equipment

A switching regulator including a control circuit including a deviation detector for detecting a deviation between the detection value of the controlled variable and the reference value, a phase difference signal generator for generating a phase difference signal having a pulse width corresponding to the deviation, a reference signal shaper for shaping two reference signals of the same waveform having a phase difference corresponding to the pulse width of the phase difference signal, and a control signal generator for ON/OFF control of switching elements corresponding to the reference signals for controlling a switching circuit having transistors connected as the switching elements in a bridge formation, the switching elements are all driven with an equal ON/OFF ratio, the phase difference between the ON instructions to the two sets of the switching elements is controlled to control the output so that the control of the switching regulator is accomplished not by the pulse width for driving the switching elements but by the overlapping width of ON times of the two switching elements.

Switching regulator

Growing community of inventors

Tokyo, Japan

Masami Arai